"Isoxazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.
| Descriptor ID |
D007555
|
| MeSH Number(s) |
D03.383.129.385
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Isoxazoles".
Below are MeSH descriptors whose meaning is more specific than "Isoxazoles".
This graph shows the total number of publications written about "Isoxazoles" by people in this website by year, and whether "Isoxazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 6 | 0 | 6 |
| 1997 | 8 | 2 | 10 |
| 1998 | 6 | 2 | 8 |
| 1999 | 5 | 2 | 7 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 2 | 5 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isoxazoles" by people in Profiles.
-
Efficacy and safety of oral type II topoisomerase inhibitors versus ceftriaxone-based regimens for the treatment of gonorrhoea: A systematic review and meta-analysis of randomised controlled trials. J Infect Chemother. 2026 Sep; 32(9):103038.
-
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
-
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecol Oncol. 2020 09; 158(3):769-775.
-
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
-
Platelet-type 12-lipoxygenase deletion provokes a compensatory 12/15-lipoxygenase increase that exacerbates oxidative stress in mouse islet ß cells. J Biol Chem. 2019 04 19; 294(16):6612-6620.
-
Inhibition of 12/15-Lipoxygenase Protects Against ß-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes. 2017 11; 66(11):2875-2887.
-
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep. 2017 03 15; 7(1):201.
-
First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. J Psychopharmacol. 2017 04; 31(4):434-441.
-
Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol. 2016 11; 121(2):232-238.
-
Ethanol-Induced Motor Impairment Mediated by Inhibition of a7 Nicotinic Receptors. J Neurosci. 2016 07 20; 36(29):7768-78.